ClinicalTrials.gg

Nasopharyngeal Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 226 studies for Nasopharyngeal Neoplasms across more than 10 countries. 42 are recruiting or about to start. 99 of them are mainly about Nasopharyngeal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Nasopharyngeal Carcinoma too: 861 studies, 301 open.

Status

Completed
98
Status unknown
48
Recruiting
32
Terminated
18
Active, not recruiting
16
Not yet recruiting
9

Phase

Phase 2
103
Phase 1
47
Phase 3
23
Phase 4
5
Early Phase 1
1

Where

China
83
United States
82
Canada
16
Singapore
16
Hong Kong
10
France
9

Who develops what

Add Nasopharyngeal Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DocetaxelRecent, repeated
Evidence
  • NCT06892431 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Docetaxel injection” · registered Mar 2025
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
  • NCT02611960 · Merck & Co., Inc · Phase 3 · comparator · “Docetaxel” · registered Nov 2015
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized22 studies
GemcitabineRecent, repeated
Evidence
  • NCT06892431 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Gemcitabine hydrochloride for injection” · registered Mar 2025
  • NCT05198531 · Sino Biopharmaceutical Limited · Phase 2 · background · “Gemcitabine hydrochloride injection” · registered Jan 2022
  • NCT03924986 · BeOne Medicines · Phase 3 · background · “Gemcitabine” · registered Mar 2019
  • NCT02611960 · Merck & Co., Inc · Phase 3 · comparator · “Gemcitabine” · registered Nov 2015
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed22 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Nasopharyngeal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 12 open · Antimetabolites 3 open · Angiogenesis inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 1 open · Antimitotic agents 16

Coming up

11studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger. 3 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.

Recruiting studies that take each age, of 32
AgeWomenMen
102 (6%)2 (6%)
1828 (88%)28 (88%)
3032 (100%)32 (100%)
4032 (100%)32 (100%)
5032 (100%)32 (100%)
6532 (100%)32 (100%)
7522 (69%)22 (69%)
8514 (44%)14 (44%)

Across all 226 studies, recruiting or not: 39% stop at 75 or younger and 15% at 65; 13% take children; <1% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Nasopharyngeal Neoplasms studies take

Of 33 phase 2 interventional studies under Nasopharyngeal Neoplasms, half reached primary completion within 55 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 255 mo31–124 · 33 studies——
Interventional, no phase93 mo31–143 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 226. Browse all 226 → or search them.